Table 1 Characteristics of study subjects based on the number of eyes with visual field damage.

From: Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study

 

VFD-0 (n = 378)

VFD-1 (n = 689)

VFD-2 (n = 1776)

p-value

Age (years)

Mean (SD)

62.4 (11.4)

65.0 (11.8)

68.8 (11.7)

<0.001*

Min-max

23.6–91.1

23.8–100.0

18.6–100.6

 

Male gender

186 (49.2)

338 (50.5)

876 (49.3)

0.863^

Race

Asian

0 (0.0)

2 (0.3)

3 (0.2)

0.876^

Black

1 (0.3)

4 (0.6)

9 (0.5)

 

Caucasian

377 (99.7)

663 (99.1)

1764 (99.3)

 

BCVA (Decimal fraction) [Snellen]

Mean (SD)

0.93 (0.1)

[20/21.5 (20/200)]

0.87 (0.2) [20/23.0 (20/100)]

0.79 (0.2) [20/25.3 (20/100)]

<0.001*

Min-max

0.04–1.0

[20/500–20/20]

0.02–1.0

[20/1000–20/20]

0.00–1.0 [0.0 –20/20]

 

Newly Diagnosed

20 (5.29)

39 (5.83)

108 (6.08)

0.557^

Previous treatment#

   

<0.001^

None

22 (6.2)

21 (3.3)

27 (1.6)

 

Only medical

279 (77.9)

419 (66.5)

1194 (71.6)

 

Only surgical

8 (2.2)

20 (3.2)

60 (3.6)

 

Medical and surgical

49 (13.7)

170 (27.0)

386 (23.2)

 

Type of surgery (n = 693)

Trabeculectomy

21 (36.8)

95 (50.0)

268 (60.1)

<0.001^

Viscocanalostomy

0 (0.0)

2 (1.1)

1 (0.2)

0.537^

Deep-sclerectomy

0 (0.0)

3 (1.6)

16 (3.6)

0.053^

Argon laser trabeculoplasty

40 (70.2)

117 (61.6)

205 (46.0)

<0.001^

Glaucoma medication

328 (91.6)

589 (93.5)

1581 (94.8)

0.017^

β-blockers

93 (28.4)

152 (25.9)

364 (23.0)

0.025^

CAIs

22 (6.7)

57 (9.7)

214 (13.5)

<0.001^

Prostaglandin analogues

167 (50.9)

275 (46.7)

830 (52.5)

0.163^

Parasympathomimetic drugs

5 (1.5)

28 (4.8)

53 (3.4)

0.456^

Prostaglandin + β-blocker FC

47 (14.3)

127 (21.6)

327 (20.7)

0.045^

Alpha agonist + β-blocker FC

10 (3.1)

30 (5.1)

72 (4.6)

0.432^

CAI + β-blocker FC

56 (17.1)

129 (21.9)

416 (26.3)

<0.001^

Systemic treatment

234 (61.9)

430 (64.5)

1299 (73.5)

<0.001^

Glaucoma family history

154 (40.7)

242 (36.2)

614 (34.6)

0.029^

Myopia

49 (13.0)

112 (16.7)

327 (18.4)

0.012^

Diabetes

40 (10.6)

75 (11.2)

287 (16.2)

<0.001^

Hypertension

186 (49.2)

331 (49.5)

998 (56.2)

0.001^

  1. Min, minimum value; max, maximum value; SD, standard deviation; BCVA, best corrected visual acuity; VFD-0, patients without visual field damage in any eye; VFD-1, patients with visual field damage in one eye; VFD-2, patients with visual field damage in both eyes; CAI, carbonic anhydrase inhibitor; FC, fixed combination; *, linear regression model; ^, chi square test for trend; #in patients not newly diagnosed.
Back to article page